Early benefit assessment of medications
The price of new drugs in Germany depends on the result of the so-called early benefit assessment. The legal basis for this is the “Act on the Reform of the Market for Medicinal Products (AMNOG).” Here you can find information on medications that have been assessed by the German Institute for Quality and Efficiency in Health Care (IQWiG, Germany) in the last few years.
Early benefit assessment of medications from A to Z
Popular in Early benefit assessment of medications
Drugs assessed by IQWiG
Since early 2011, the added benefit of most medications containing new active ingredients must be assessed as soon as they enter the market in German...
Enzalutamide (Xtandi) for the treatment of advancing prostate cancer
Enzalutamide (trade name: Xtandi) has been approved in Germany since June 2013 for the treatment of metastatic prostate cancer if conventional hormon...
Nivolumab (Opdivo) for the treatment of melanoma
Nivolumab (trade name: Opdivo) has been approved in Germany since June 2015 for the treatment of advanced melanoma in adults. Since May 2016, it has ...
Atezolizumab (Tecentriq) for the first-line treatment of advanced lung cancer
Atezolizumab (trade name: Tecentriq) has been approved in Germany since September 2019 for the first-line treatment of advanced non-small-cell and ad...
Dulaglutide (Trulicity) for the treatment of type 2 diabetes
Dulaglutide (trade name: Trulicity) has been approved in Germany since November 2014 for the treatment of type 2 diabetes when diet and exercise alon...
Bosutinib (Bosulif) for the treatment of chronic myeloid leukemia
Bosutinib (trade name: Bosulif) has been approved in Germany since March 2013 for the treatment of Philadelphia chromosome-positive, chronic myeloid ...